mRNA Therapeutics Market Forecast Projects 5x Growth by 2035
A market research firm is projecting mRNA therapeutics will quintuple in value by 2035 — a bold number that deserves more scrutiny than the press release gives it.
Explanation
Nova One Advisor pegs the global mRNA therapeutics market at $17.25 billion in 2025, growing to $83.49 billion by 2035 at a compound annual growth rate (CAGR) of 17.08% — meaning the market would grow by roughly the same percentage each year for a decade.
mRNA therapeutics use genetic instructions (messenger RNA) to tell your cells to produce a specific protein — either to fight a disease or train the immune system. COVID-19 vaccines from Pfizer/BioNTech and Moderna were the technology's breakout moment, and the pipeline has since expanded into cancer, rare diseases, and infectious disease.
The "so what" today: this forecast is a signal of investor and industry sentiment, not a verified roadmap. A 17% annual growth rate held over ten years is an aggressive assumption. It bakes in successful clinical trials, regulatory approvals, and broad reimbursement for non-vaccine mRNA drugs — none of which are guaranteed. The current $17B baseline is itself heavily propped up by residual COVID vaccine revenues that are declining.
What would actually validate this trajectory: watch for mRNA cancer therapeutics (like Moderna's mRNA-4157 with Merck) clearing Phase 3 trials, and for non-vaccine mRNA drugs reaching commercial scale. Those are the real milestones. Until then, treat this number as an optimistic ceiling, not a floor.
Nova One Advisor's $83.49B by 2035 projection implies a sustained 17.08% CAGR from a $17.25B 2025 base — a figure that warrants decomposition before anyone builds a thesis around it.
The current baseline is structurally fragile. The bulk of today's mRNA revenue traces back to COVID-19 vaccine contracts, which are in secular decline. Moderna's 2023 revenues dropped ~64% YoY as pandemic-era procurement dried up. Any credible 10-year model needs to show where the replacement volume comes from — and the honest answer is: mostly from pipeline assets that haven't cleared Phase 3 yet.
The bull case is real but conditional. Personalized cancer vaccines (Moderna/Merck's mRNA-4157/V940 in adjuvant melanoma, now in Phase 3) represent the highest-value near-term catalyst. If that readout is positive and the label is broad, it reshapes the revenue curve materially. Beyond oncology, mRNA-based protein replacement therapies for rare diseases (e.g., propionic acidemia, PA) and next-gen infectious disease vaccines (RSV, influenza, HIV) are in various trial stages. Collectively, they could justify a large market — but the timing and attrition assumptions in a 17% CAGR model are doing a lot of heavy lifting.
Delivery remains the field's persistent bottleneck. Lipid nanoparticle (LNP) formulations dominate but carry tolerability and tissue-targeting limitations outside intramuscular injection. Extrahepatic delivery — reaching tumors, lungs, or the CNS — is still largely preclinical or early clinical. Whoever cracks targeted delivery unlocks the real addressable market; until then, the TAM is narrower than the headline suggests.
The forecast also ignores competitive displacement risk: saRNA (self-amplifying RNA), circular RNA, and DNA-based platforms are all chasing the same indications with potentially superior durability or tolerability profiles.
Watch the Moderna/Merck Phase 3 melanoma data and any FDA accelerated approval decisions in mRNA oncology over the next 18 months. Those outcomes will either anchor or deflate the upper bound of this forecast faster than any analyst model will.
Reality meter
Why this score?
Trust Layer Score basis
A detailed evidence breakdown is being added. For now, the score basis is the source list below and the reality meter above.
- 46 sources on file
- Avg trust 42/100
- Trust 40–95/100
Time horizon
Community read
Glossary
- CAGR
- Compound Annual Growth Rate; the average annual rate at which an investment or metric grows over a specified period, accounting for compounding effects.
- mRNA
- Messenger RNA; a type of genetic material that carries instructions from DNA to cells to produce specific proteins, used as the basis for vaccines and therapeutic treatments.
- Phase 3
- The third stage of clinical drug trials where a treatment is tested on larger patient populations to confirm effectiveness and monitor side effects before seeking regulatory approval.
- Lipid nanoparticle (LNP)
- A tiny spherical delivery vehicle made of lipids (fats) that encapsulates and protects mRNA, allowing it to enter cells and avoid immune system degradation.
- TAM
- Total Addressable Market; the total revenue opportunity available for a product or service if it achieves 100% market penetration in its target segment.
- saRNA
- Self-amplifying RNA; a genetic platform that can replicate itself inside cells, potentially requiring lower doses than standard mRNA while maintaining therapeutic effect.
- Accelerated approval
- An FDA regulatory pathway that allows faster approval of drugs for serious conditions based on preliminary evidence, with continued monitoring post-approval.
What's your read?
Your read shapes future topic weighting.
Your vote feeds topic weights, community direction and future prioritisation. Open community direction
Sources
- Tier 3 mRNA Therapeutics Market Size to Hit USD 83.49 Billion by 2035
- Tier 3 Biotechnology News -- ScienceDaily
- Tier 3 Colossal Biosciences announces ‘de-extinction’ plan for African bluebuck | CNN
- Tier 3 Clarkson University Researchers Contribute to Breakthrough Biosensor Technology Published in Nature Biotechnology | Clarkson University
- Tier 3 Biotech and Pharma Industry News | BioPharma Dive
- Tier 3 ScienceDaily: Your source for the latest research news
- Tier 3 Fierce Biotech News & Reports
- Tier 1 Nature Biotechnology
- Tier 3 2024 in science - Wikipedia
- Tier 3 Top Biotech Startups 2026: An Analysis of Emerging Trends | IntuitionLabs
- Tier 3 Study: CRISPR gene editing leads to improvements in vision for people with inherited blindness | Ophthalmology Times - Clinical Insights for Eye Specialists
- Tier 3 A one-time treatment tweaked their genes — and lowered their cholesterol
- Tier 3 Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing - Intellia Therapeutics
- Tier 3 Potential Cure for HIV from CRISPR Gene Editing in Phase 1/2 Clinical Trial | Contagion Live
- Tier 3 Milestone for Crispr: First-of-Its-Kind Gene Editing Treatment Successfully Passes Clinical Trial
- Tier 3 CRISPR gene editing - Wikipedia
- Tier 3 Intellia CRISPR drug succeeds in late-stage study against rare swelling disorder | BioPharma Dive
- Tier 3 Discovery broadens scope of use of CRISPR gene editing | ScienceDaily
- Tier 3 Scientists just made CRISPR three times more effective | ScienceDaily
- Tier 3 Synthetic Biology Market Size, Share, Industry Growth 2035
- Tier 3 Synthetic Biology Market Size, Share & Growth Trends 2035
- Tier 3 Flagship Pioneering Launches Serif Biomedicines to Establish Modified DNA as a New Biotechnology
- Tier 3 SynbiTECH 2026 | The Must-Attend Synthetic Biology Conference
- Tier 3 2026 Synthetic Biology: Engineering, Evolution, & Design (SEED) | AIChE
- Tier 3 Synthetic Biology Market worth $31.52 billion in 2029 | Press Releases | reformer.com
- Tier 3 Synthetic Biology Market Analysis 2026-2031: Genome Engineering Accounts for 33.21% Share, with Asia-Pacific as the Fastest-Growing Region, Says Mordor Intelligence
- Tier 3 Global DNA Read, Write and Edit Market to Surge to $67.7 Billion by 2030, Driven by CRISPR Advances, Genomic Diagnostics and Expanding Clinical Applications
- Tier 3 North America Gene Synthesis Market Outlook 2026-2034
- Tier 3 Synthetic Biology Product Market is Going to Boom | Amyris , Zymergen
- Tier 3 List of Funded Biotech Startups (2026) - Fundraise Insider
- Tier 3 Early-stage funding slumps toward post-pandemic low, piling more pressure on biotech startups
- Tier 3 The Week’s 10 Biggest Funding Rounds: SiFive Leads With $400M For Custom Chip Designs As Aviation, Biotech And Defense Startups Also Raise Big
- Tier 3 1,200+ Funded Biotech Startups 2026 | Verified Contacts
- Tier 3 Biotech Valuation Benchmarks for Series A and B in 2026
- Tier 3 The Week’s 10 Biggest Funding Rounds: AI, Autonomy And Biotech Top The Ranks
- Tier 3 Biotechnology Startup Funding 2025-2026 – New Market Pitch
- Tier 3 Jeito Capital, prominent biotech investor, raises $1.2B for next fund | BioPharma Dive
- Tier 3 Stanford's James Zou targets $1B valuation for AI physiology startup backed by Nature-published research and FDA-cleared cardiac AI
- Tier 3 DNA origami vaccines could be the next leap beyond mRNA | ScienceDaily
- Tier 1 Engineered cells as programmable mRNA delivery vehicles | Nature Reviews Bioengineering
- Tier 3 AI, CRISPR, and mRNA Driving Biotech’s Smartest Decade Yet | BioPharm International
- Tier 3 New Research Challenges Understanding of mRNA Vaccines and Establishes Innovative Way to Make Them More Effective | Mount Sinai - New York
- Tier 3 mRNA Delivery Technology Landscape 2026 — PatSnap Eureka | PatSnap
- Tier 3 Next-generation neoantigen mRNA vaccines: Immuno-engineering strategies for precision cancer immunotherapy | Cellular Oncology | Springer Nature Link
- Tier 3 After a year of turmoil, cancer researchers see promising signs for mRNA vaccines | CNN
- Tier 3 Next-generation neoantigen mRNA vaccines: Immuno-engineering strategies for precision cancer immunotherapy - PMC
Optional Submit a prediction Optional: add your prediction on the core question if you like.
Prediction
Will the global mRNA therapeutics market exceed $50 billion in annual revenue before 2032?